EpiCept gets milestone payment for successful Azixa brain cancer data

By Elaine Rigoli

Tampa, Fla., Sept. 25 - EpiCept Corp. said Monday that Myriad Genetics, Inc. reported positive clinical results for Azixa, a compound discovered by EpiCept and licensed to Myriad as part of an exclusive, worldwide development and commercialization agreement.

Based on these results, Myriad intends to begin phase 2 clinical trials for the drug this fall, triggering a milestone payment to EpiCept.

Myriad Genetics has reported that in a phase 1 study of Azixa in cancer that has metastasized to the brain, the drug achieved its maximum tolerated dose in patients.

Myriad also noted a measured reduction in tumor size in certain patients, suggesting evidence of activity.

The Englewood Cliffs, N.J., pharmaceutical company said its proprietary apoptosis screening technology can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells through the use of chemical genetics and its proprietary live cell high-throughput caspase-3 screening technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.